Overview

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

Status:
NOT_YET_RECRUITING
Trial end date:
2031-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Phase:
PHASE3
Details
Lead Sponsor:
Janssen Research & Development, LLC